Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome

被引:40
|
作者
Rogolino, A
Coccia, ME
Fedi, S
Gori, AM
Cellai, AP
Scarselli, GF
Prisco, D
Abbate, R
机构
[1] Univ Florence, Azienda Osped Careggi, Thrombosis Ctr, Dept Med & Surg Crit Care, I-50121 Florence, Italy
[2] Univ Florence, Dept Obstet & Gynecol, I-50121 Florence, Italy
关键词
coagulation; fibrinolysis; severe ovarian hyperstimulation syndrome; tissue factor; tissue factor pathway inhibitor;
D O I
10.1097/00001721-200304000-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During ovarian gonadotrophin stimulation for ovulation induction or in vitro fertilization, a clinical severe ovarian hyperstimulation syndrome (OHSS) may occur. Only few studies have investigated the mechanism responsible for the alterations of the haemostatic system in women affected by severe OHSS. The aim of the present study was to investigate the correlation between the magnitude of ovarian stimulation and the increase in fibrin formation and degradation in severe OHSS. Twenty-five patients (age range 23-43 years) who were hospitalized for severe OHSS, 25 women undergoing in vitro fertilization who did not develop OHSS (case-control group) and 25 healthy age-matched women (healthy control group) were investigated. On the day of admission a number of haemostatic markers, including D-dimer, thrombin-antithrombin complexes (TAT), prothrombin fragment 1 + 2 (F1 + 2), plasmin-antiplasmin complexes (PAP), tissue factor (TF), tissue factor pathway inhibitor (TFPI) and von Willebrand factor antigen (vWF), were examined. In patients with severe OHSS, TF, D-dimer, TAT, F1 + 2, PAP and vWF antigen plasma levels were significantly higher than those observed both in the case-control group and in healthy controls, whereas TFPI levels were significantly lower (P < 0.005) with respect to both case-controls and healthy controls. D-Dimer levels were related with serum oestradiol levels and oocyte number recovered (r = 0.45, P < 0.001 and r = 0.47, P < 0.001, respectively). D-Dimer and TAT levels were significantly (P < 0.05 and P < 0.005, respectively) higher in OHSS patients with unsuccessful pregnancy outcome (D-dimer, 226.5, 56-1449 ng/ml; TAT, 19.8, 3.1-82.6 mug/l) with respect to those with successful outcome of pregnancy (D-dimer, 145, 29-330 ng/ml; TAT, 5.0,1.0-19.6 mug/l). Our data indicate that a marked hypercoagulability with alterations of TF and TFPI levels is detectable in patients with severe OHSS and that it is related to the clinical outcome. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 50 条
  • [41] Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders
    Özcan, MA
    Çömlekçi, A
    Demirkan, F
    Yüksel, F
    Sari, I
    Demir, T
    Özsan, GH
    Örük, G
    Yesil, S
    Ündar, B
    THROMBOSIS RESEARCH, 2003, 110 (04) : 243 - 247
  • [42] Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias
    Zitoun, D
    Bara, L
    Basdevant, A
    Samama, MM
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (01) : 77 - 81
  • [43] Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease
    Eling, M
    Stephens, AC
    Oragui, EE
    Rivers, RPA
    Levin, M
    THROMBOSIS AND HAEMOSTASIS, 2001, 85 (02) : 240 - 244
  • [44] Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency
    Mehic, Dino
    Tolios, Alexander
    Hofer, Stefanie
    Ay, Cihan
    Haslacher, Helmuth
    Rejto, Judit
    Ouwehand, Willem H.
    Downes, Kate
    Haimel, Matthias
    Pabinger, Ingrid
    Gebhart, Johanna
    BLOOD ADVANCES, 2021, 5 (02) : 391 - 398
  • [45] Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates
    Cvirn, G
    Gallistl, S
    Leschnik, B
    Muntean, W
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (02) : 263 - 268
  • [46] Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers
    Harenberg, J
    Jeschek, M
    Acker, M
    Malsch, R
    Huhle, G
    Heene, DL
    BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (01) : 49 - 56
  • [47] Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls
    Yamanobe, F
    Mochida, S
    Ohno, A
    Ishikawa, K
    Fujiwara, K
    THROMBOSIS RESEARCH, 1997, 85 (06) : 493 - 501
  • [48] Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock
    Matyal, R
    Vin, Y
    Delude, RL
    Lee, C
    Creasey, AA
    Fink, MP
    INTENSIVE CARE MEDICINE, 2001, 27 (08) : 1274 - 1280
  • [49] Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency
    Castillo, Michelle M.
    Yang, Qiuhui
    Zhan, Min
    Pan, Amy Y.
    Lawlor, Michael W.
    Mast, Alan E.
    Sood, Rashmi
    BLOOD ADVANCES, 2019, 3 (03) : 489 - 498
  • [50] The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients
    Brown, JR
    Kuter, DJ
    THROMBOSIS AND HAEMOSTASIS, 2001, 85 (06) : 979 - 985